Link Cell Therapies is a biotechnology company based in South San Francisco, California that was founded in 2022 by Robbie Majzner, MD and Crystal Mackall, MD at Stanford University. Link's proprietary logic-gating technologies allow for safe targeting of multiple antigens that are co-expressed selectively on cancer cells, thereby reducing the risk of on-target, off-tumor toxicity. This enables discovery of an entirely new landscape of 'clean' target pairs, and development of next-generation CAR-T therapeutics for solid and liquid cancers. Link's team features industry-leading scientists collaborating with top-tier advisors and life science financial and strategic investors committed to improving outcomes for cancer patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/15/25 | $60,000,000 | Series A |
Johnson & Johnson Innovation Samsara BioCapital Sheatree Capital Wing Venture Capital | undisclosed |
